|
Da Zen Theranostics, Inc. was founded by two professors, Dr. Leland W.K. Chung and Dr. Haiyen E. Zhau, who have devoted their academic careers (over 50 years each) to cancer research. The company was formed with the intention of bringing effective cancer treatment to late stage cancer patients. The husband-and-wife team named their company Da Zen 大 仁 which means ‘great kindness’ in Chinese. Dr. Chung has passed away in May 2021. However, the current management team is carrying on to fulfill his dream to bring his cancer solutions to the world.
Da Zen Theranostics, Inc. (U.S.) was initially incorporated in the State of Delaware in 2012 as an LLC, but later converted to a C-Corp in 2017. Da Zen (U.S.) has a wholly owned subsidiary in China under the name De Zen (China) Medical Technology Co Ltd. The subsidiary shares patent licensing rights and ownership with the U.S. parent company. Da Zen (China) Medical Technology Co Ltd started its operations in Chengdu in January of 2019. The total investment by the parent company will eventually reach 50M RMB. The Da Zen Theranostics Inc,, which owns the Chinese Subsidiary 100%, has no institutional investors and is totally funded by friends and family. After completing Phase II Trials, the company will initiate its first Series A preferred funding to commercialize its drug products. |
